New strategies for closing the gap of measles susceptibility in infants: Towards vaccines compatible with current vaccination schedules

Karim C. El Kasmi, Claude P. Muller*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

19 Citations (Scopus)

Abstract

Peptides representing epitopes of the measles virus glycoproteins have been designed to induce neutralizing and protective antibodies. Those that escape recognition by passively acquired anti-whole virus antibodies could potentially be used as components of a 'pre-vaccine' that could be given during early childhood irrespective of persisting maternal antibodies. Unlike vaccines based on recombinant proteins, epitope-based vaccines can be designed to be compatible with a subsequent boost with the standard life attenuated vaccine. Although synthetic peptides may induce only short-term immunity they have the potential to close in young infants the gap of vulnerability until the standard live attenuated vaccine can be given at 9 or 15 months of age.

Original languageEnglish
Pages (from-to)2238-2244
Number of pages7
JournalVaccine
Volume19
Issue number17-19
DOIs
Publication statusPublished - 21 Mar 2001
Externally publishedYes

Keywords

  • Maternal antibodies
  • Measles virus
  • Synthetic peptides

Fingerprint

Dive into the research topics of 'New strategies for closing the gap of measles susceptibility in infants: Towards vaccines compatible with current vaccination schedules'. Together they form a unique fingerprint.

Cite this